ABVC BioPharma Inc is a clinical-stage biopharmaceuticals company with an active pipeline of six drugs and one medical device (ABV-1701/Vitargus) under development... Show more
Get AI intraday signals
A.I. Advisor
published Earnings
ABVC is expected to report earnings to rise 900.00% to -60 cents per share on August 15
Q2'23
Est.
$-0.60
Q1'23
Missed
by $0.01
Q4'22
Est.
$-0.15
Q3'22
Beat
by $0.09
Q2'22
Beat
by $0.06
The last earnings report on May 15 showed earnings per share of -5 cents, missing the estimate of -5 cents. With 100.63K shares outstanding, the current market capitalization sits at 15.13M.